Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given a consensus recommendation of “Buy” by the nine research firms that are covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $15.97.

Several brokerages recently commented on VYGR. Cantor Fitzgerald initiated coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $5.73 price objective for the company. Leerink Partners began coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. Wedbush assumed coverage on Voyager Therapeutics in a research note on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th.

Voyager Therapeutics Trading Up 0.2 %

Shares of VYGR opened at $5.07 on Friday. The stock’s 50 day moving average is $5.91 and its two-hundred day moving average is $6.72. Voyager Therapeutics has a twelve month low of $4.99 and a twelve month high of $10.66. The firm has a market capitalization of $276.97 million, a PE ratio of 7.14 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the prior year, the company posted ($0.59) earnings per share. On average, sell-side analysts predict that Voyager Therapeutics will post -0.89 EPS for the current year.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 10,778 shares of company stock valued at $58,548 over the last quarter. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Great Point Partners LLC acquired a new stake in shares of Voyager Therapeutics during the second quarter worth $12,668,000. FMR LLC lifted its position in Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after buying an additional 19,622 shares during the period. Geode Capital Management LLC boosted its stake in Voyager Therapeutics by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after buying an additional 6,740 shares during the last quarter. Armistice Capital LLC grew its holdings in Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after buying an additional 528,000 shares during the period. Finally, Barclays PLC increased its stake in shares of Voyager Therapeutics by 55.8% during the 3rd quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after acquiring an additional 37,398 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.